Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Feb 9, 2015
- Achillion achieves 100% SVR12 in six-week regimen with combination of ACH-3102 and sofosbuvir for treatment-naïve genotype 1 HCV -- Achillion to initiate 4-week treatment regimens based on the strength of ACH-3102 antiviral data - NEW HAVEN, Conn., Feb. 9, 2015 (GLOBE NEWSWIRE) --Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announ...
PDF
Feb 6, 2015
NEW HAVEN, Conn., Feb. 6, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Leerink Global Healthcare Conference on Thursday, February 12, 2015 at 8:55 a....
PDF
Dec 22, 2014
- A six-week dual NS5A - Nuc regimen of ACH-3102 and sofosbuvir was safe and well-tolerated with 100 percent SVR4 for treatment-naïve genotype 1 HCV ("Proxy Study")- ACH-3422 proof-of-concept trial showed it was safe and well-tolerated at doses of 50 mg-700 mg once daily achieving 4.8 log10 reduction with 700 mg dose after 14 days -- Conferenc...
PDF
Nov 25, 2014
NEW HAVEN, Conn., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at two upcoming investor conferences: 2014 Deutsche Bank BioFEST on Monday, December 1, 2014 at 9:15 a.m. ET at the Four Seasons Hotel in Boston, MA; and ...
PDF
Nov 8, 2014
- Achillion Achieves 100% SVR12 in Eight-Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study") Including Nine of 12 Patients With Viral Loads Higher Than 6 Million IU/ml at Baseline -- Reports Additional Preclinical Results for ACH-3422, Uridine-Analog Nucleotide NS5B Polymerase Inhibit...
PDF
Nov 6, 2014
NEW HAVEN, Conn., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts are scheduled for presentation at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, CA, December 6 - 9. The abstracts are now available at http://www.hematology.org/Annual-Meeting/. ...
PDF
Nov 4, 2014
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -- Advancement of novel platform for complement factor D inhibitors for the oral treatment of immune-related rare diseases - NEW HAVEN, Conn., Nov. 4, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceu...
PDF
Oct 8, 2014
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV - - Three preclinical posters on ACH-3422, uridine-analog nucleotide prodrug, to be presented - NEW HAVEN, Conn., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Achillion Ph...
PDF
Aug 19, 2014
NEW HAVEN, Conn., Aug. 19, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent & Trademark Office has granted Achillion U.S. Patent No. 8,809,313, covering composition-of-matter and method of use claims for ACH-3102 and structurally related NS5A inhibitor compounds. ACH-3102 is Achillion's sec...
PDF
Aug 15, 2014
NEW HAVEN, Conn., Aug. 15, 2014 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced interim results from an ongoing Phase 2 proxy study evaluating ACH-3102, Achillion's second-generation NS5A inhibitor, in combination with sofosbuvir, without ribavirin, for eight weeks of treatment in patients with treatment-naïve...
PDF
FirstPrevious
...
7
...
NextLast